Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.
Clinical Trials Arena on MSN
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...
At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results